Material Agreement, Financial Obligation, Material Impairments (Form 8-K)

Item 1.01. Entry into a Material Definitive Agreement.

On February 4, 2026, Molina Healthcare, Inc. (the "Company") entered into a First Amendment to its Credit Agreement (the "Amended Credit Agreement") among the Company, as the Borrower, the Lenders (as defined therein) party thereto, and Truist Bank, as Administrative Agent. The Amended Credit Agreement amends the Company's prior Credit Agreement dated as of November 20, 2025 (the "Prior Credit Agreement"). The terms of the Amended Credit Agreement are substantially similar to the terms of the Prior Credit Agreement, except that Section 6.2 was revised to temporarily reduce the quarterly required minimum interest coverage ratio from 3.00:1.00 to (a) with respect to each fiscal quarter ending March 31, 2026 through and including December 31, 2026, 1.75:1.00, (b) with respect to fiscal quarter ending March 31, 2027, 2.00:1.00, (c) with respect to fiscal quarter ending June 30, 2027, 2.50:1.00, and (d) with respect to fiscal quarter ending September 30, 2027, 2.75:1.00.

The foregoing summary of the Amended Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amended Credit Agreement, a copy of which is being filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amended Credit Agreement is incorporated by reference into this Item 2.03.

Item 2.06. Material Impairments

On February 5, 2026, the Company concluded that it will record in the first quarter of 2026 an estimated non-cash, pre-tax impairment charge of approximately $93 million, attributable to certain of its intangible assets. This impairment charge results from the Company's decision to exit the Medicare Advantage Prescription Drug product for 2027 as that product does not align with the Company's strategic shift to focus exclusively on dual eligible members in Medicare. This charge will be recorded outside of adjusted net income. "Adjusted net income" is defined in the Company's fourth quarter earnings release issued on February 5, 2026, and included as an exhibit to the Form 8-K filed on that same date.